Is Nivolumab Given Intravenously, Not as a Pill?
Yes, nivolumab (brand name Opdivo) is administered intravenously (IV) and is not available as an oral pill. It requires infusion at a healthcare facility, typically every 2, 4, or 6 weeks depending on the dose and cancer type.[1]
How Is Nivolumab Administered?
Nivolumab is given as an IV infusion over 30 minutes. Doses range from 240 mg every 2 weeks to 480 mg every 4 weeks for most indications, such as melanoma, lung cancer, or renal cell carcinoma. No subcutaneous or oral formulations exist.[1][2]
Why No Pill Form?
As a PD-1 inhibitor monoclonal antibody, nivolumab must be delivered intravenously to ensure it reaches the bloodstream intact. Proteins like this break down in the digestive system if taken orally, making pills ineffective.[2]
What Happens If Someone Tries Taking It as a Pill?
No pill version exists, so oral use isn't possible. Attempting to misuse IV drugs orally risks no benefit and potential harm from excipients not meant for ingestion.[2]
How Long Does an Infusion Take?
Infusions last about 30 minutes, but premedication and monitoring add time, often totaling 1-2 hours per visit.[1]
Who Makes Nivolumab and Are There Alternatives?
Bristol Myers Squibb manufactures Opdivo. Competitors include IV PD-1/PD-L1 inhibitors like pembrolizumab (Keytruda, also IV) or cemiplimab (Libtayo, IV). No oral PD-1 inhibitors are approved yet, though some are in trials.[1][3]
Patent Status for Nivolumab
Key U.S. patents on nivolumab expire in 2028-2034, with some facing challenges. Check DrugPatentWatch.com for expiry details and generics.[4]
[1]: Opdivo Prescribing Information, Bristol Myers Squibb (fda.gov).
[2]: FDA Label for Opdivo (accessdata.fda.gov).
[3]: NCCN Guidelines for Non-Small Cell Lung Cancer (nccn.org).
[4]: DrugPatentWatch.com (drugpatentwatch.com/p/tradename/OPDIVO).